Neuroscience
From yesterday's New York Times:
Jump-Start on Slow Trek to Treatment for a Disease
By DONALD G. McNEIL Jr.
Published: January 8, 2008
Last month, the Bill and Melinda Gates Foundation donated $19 million to the Drugs for Neglected Diseases Initiative to further one of its goals: finding a new drug for African sleeping sickness.
Not that $19 million will come close to doing that. Even if a miracle cure is found, it will take lab work and clinical trials that could easily cost $100 million to prove it is really a miracle and not the Vioxx of the African savannah.
But the gift spotlights just how tricky the search for new treatments can be when the disease is fearsome but nearly forgotten because its victims are poor and obscure.
[ ... Read the full article ... ]
- Neuropsychology Abstract Of The Day: Alzheimer's Disease Pharmacologic Strategies
New pharmacological strategies for treatment of Alzheimer's disease: focus on disease-modifying drugs British Journal of Clinical Pharmacology. 2011 Oct 28; Salomone S, Caraci F, Leggio GM, Fedotova J, Drago F Abstract Current approved drug treatments...
- Methylphenidate
From The New York Times:Panel Recommends Warnings for Ritalin and Other Stimulants By THE ASSOCIATED PRESS Published: February 9, 2006 Filed at 4:13 p.m. ET WASHINGTON (AP) -- Federal science advisers voted narrowly Thursday to recommend the most serious...
- Business World: Biogen Idec, Protein Design Labs, & Daclizumab
From The Boston Globe:Biogen cuts deal to refill drug lineup Biotech to pay Calif. firm for rights to help develop MS treatment, 2 others By Jeffrey Krasner, Globe Staff The Boston Globe August 3, 2005 Making good on a promise to use a war chest of...
- Watch Out: Under-recognized, Under-treated Means Ad Blitz
An interesting piece on what's about to hit consumers: the marketing of Lunesta (eszopiclone): You May Want to Sleep on It Enter the Next 'Miracle' Drug: A Sleeping Pill You Can Take Long-Term. Ads for Lunesta Won't Likely Give That...
- Lunesta (eszopiclone)
With New Sleeping Pill, New Acceptability? By ANDREW POLLACK The New York Times 17 December 2004 Is it a wake-up call for the sleeping pill market? With Wednesday's approval of Sepracor's new drug, Lunesta, a taboo in the use of sleeping...
Neuroscience
"Sleeping sickness” (Human African Trypanosomiasis)
From yesterday's New York Times:
Jump-Start on Slow Trek to Treatment for a Disease
By DONALD G. McNEIL Jr.
Published: January 8, 2008
Last month, the Bill and Melinda Gates Foundation donated $19 million to the Drugs for Neglected Diseases Initiative to further one of its goals: finding a new drug for African sleeping sickness.
Not that $19 million will come close to doing that. Even if a miracle cure is found, it will take lab work and clinical trials that could easily cost $100 million to prove it is really a miracle and not the Vioxx of the African savannah.
But the gift spotlights just how tricky the search for new treatments can be when the disease is fearsome but nearly forgotten because its victims are poor and obscure.
[ ... Read the full article ... ]
- Neuropsychology Abstract Of The Day: Alzheimer's Disease Pharmacologic Strategies
New pharmacological strategies for treatment of Alzheimer's disease: focus on disease-modifying drugs British Journal of Clinical Pharmacology. 2011 Oct 28; Salomone S, Caraci F, Leggio GM, Fedotova J, Drago F Abstract Current approved drug treatments...
- Methylphenidate
From The New York Times:Panel Recommends Warnings for Ritalin and Other Stimulants By THE ASSOCIATED PRESS Published: February 9, 2006 Filed at 4:13 p.m. ET WASHINGTON (AP) -- Federal science advisers voted narrowly Thursday to recommend the most serious...
- Business World: Biogen Idec, Protein Design Labs, & Daclizumab
From The Boston Globe:Biogen cuts deal to refill drug lineup Biotech to pay Calif. firm for rights to help develop MS treatment, 2 others By Jeffrey Krasner, Globe Staff The Boston Globe August 3, 2005 Making good on a promise to use a war chest of...
- Watch Out: Under-recognized, Under-treated Means Ad Blitz
An interesting piece on what's about to hit consumers: the marketing of Lunesta (eszopiclone): You May Want to Sleep on It Enter the Next 'Miracle' Drug: A Sleeping Pill You Can Take Long-Term. Ads for Lunesta Won't Likely Give That...
- Lunesta (eszopiclone)
With New Sleeping Pill, New Acceptability? By ANDREW POLLACK The New York Times 17 December 2004 Is it a wake-up call for the sleeping pill market? With Wednesday's approval of Sepracor's new drug, Lunesta, a taboo in the use of sleeping...